Wall Street brokerages predict that Incyte Corporation (NASDAQ:INCY) will post $0.02 earnings per share for the current fiscal quarter, Zacks reports. Sixteen analysts have provided estimates for Incyte Corporation’s earnings, with the highest EPS estimate coming in at $0.17 and the lowest estimate coming in at ($0.08). Incyte Corporation posted earnings of $0.11 per share in the same quarter last year, which indicates a negative year over year growth rate of 81.8%. The firm is expected to announce its next earnings report on Tuesday, November 7th.

On average, analysts expect that Incyte Corporation will report full year earnings of ($0.87) per share for the current fiscal year, with EPS estimates ranging from ($0.99) to ($0.51). For the next year, analysts anticipate that the company will report earnings of $0.37 per share, with EPS estimates ranging from ($0.40) to $1.58. Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for Incyte Corporation.

Incyte Corporation (NASDAQ:INCY) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The firm had revenue of $326.40 million for the quarter, compared to analyst estimates of $318.45 million. Incyte Corporation had a negative return on equity of 21.57% and a negative net margin of 11.77%. The business’s revenue for the quarter was up 32.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.18 EPS.

Several research analysts have weighed in on the stock. Cowen and Company reissued a “buy” rating on shares of Incyte Corporation in a report on Monday, June 5th. TheStreet raised shares of Incyte Corporation from a “d+” rating to a “c” rating in a report on Wednesday, May 24th. Credit Suisse Group reissued a “buy” rating on shares of Incyte Corporation in a report on Saturday, June 10th. Argus reissued a “buy” rating and set a $150.00 price objective on shares of Incyte Corporation in a report on Wednesday. Finally, BMO Capital Markets reissued an “outperform” rating and set a $166.00 price objective (up from $155.00) on shares of Incyte Corporation in a report on Monday, June 5th. Seven research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $143.07.

Shares of Incyte Corporation (INCY) traded down 0.18% during trading on Friday, hitting $122.93. 729,676 shares of the company were exchanged. The stock’s market cap is $25.29 billion. The company’s 50-day moving average price is $128.57 and its 200 day moving average price is $130.44. Incyte Corporation has a 12 month low of $78.04 and a 12 month high of $153.15.

COPYRIGHT VIOLATION NOTICE: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/13/zacks-analysts-expect-incyte-corporation-incy-will-announce-earnings-of-0-02-per-share.html.

In related news, insider David W. Gryska sold 599 shares of Incyte Corporation stock in a transaction dated Friday, June 30th. The shares were sold at an average price of $129.74, for a total value of $77,714.26. Following the sale, the insider now directly owns 19,614 shares in the company, valued at approximately $2,544,720.36. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Bros. Advisors Lp Baker acquired 100,000 shares of the business’s stock in a transaction that occurred on Friday, September 8th. The stock was purchased at an average price of $132.00 per share, for a total transaction of $13,200,000.00. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 53,538 shares of company stock worth $7,118,269. 17.70% of the stock is currently owned by insiders.

A number of large investors have recently modified their holdings of INCY. State Street Corp lifted its position in Incyte Corporation by 110.7% in the 1st quarter. State Street Corp now owns 7,581,684 shares of the biopharmaceutical company’s stock valued at $1,013,437,000 after purchasing an additional 3,983,207 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Incyte Corporation by 22.7% during the 1st quarter. Vanguard Group Inc. now owns 15,415,857 shares of the biopharmaceutical company’s stock worth $2,060,638,000 after buying an additional 2,847,907 shares in the last quarter. Janus Henderson Group PLC raised its position in shares of Incyte Corporation by 4,570.1% during the 2nd quarter. Janus Henderson Group PLC now owns 1,045,363 shares of the biopharmaceutical company’s stock worth $131,622,000 after buying an additional 1,022,979 shares in the last quarter. Victory Capital Management Inc. bought a new stake in shares of Incyte Corporation during the 1st quarter worth about $85,751,000. Finally, Geode Capital Management LLC raised its position in shares of Incyte Corporation by 42.0% during the 1st quarter. Geode Capital Management LLC now owns 1,780,064 shares of the biopharmaceutical company’s stock worth $237,618,000 after buying an additional 526,163 shares in the last quarter. Hedge funds and other institutional investors own 91.06% of the company’s stock.

Incyte Corporation Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Get a free copy of the Zacks research report on Incyte Corporation (INCY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Incyte Corporation (NASDAQ:INCY)

Receive News & Stock Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related stocks with our FREE daily email newsletter.